Literature DB >> 3102543

Lack of desensitization of adenomatous somatotrophs to growth-hormone releasing hormone in acromegaly.

A Spada, F R Elahi, M Arosio, A Sartorio, L Guglielmino, L Vallar, G Faglia.   

Abstract

The study was undertaken to investigate whether GHRH causes desensitization in GH-secreting adenomas in analogy to the normal situation. For this purpose, GH secretion after repeated GHRH administration to acromegalic patients in vivo and cultured adenomatous somatotrophs in vitro was studied. Six acromegalic patients and 6 normal subjects received 3 consecutive 50 micrograms GHRH rapid iv injections at 2-h intervals. Blood samples were drawn at 0, 15, 30, 60, and 120 min after each dose. The acromegalic patients had variable responses to the first injection and in each patient the second and third injections elicited serum GH responses that were quite similar to those after the first one. The GH increment, evaluated as net incremental area under the curve (mean +/- SE; nanograms per ml/120 min) was 2660 +/- 1501 after the first injection, 2176 +/- 1378 after the second injection, and 1978 +/- 1191 after the third injection; P = NS. On the contrary, in normal subjects a marked elevation of GH was observed only after the first injection (net incremental area under the curve, mean +/- SE after the first injection: 710 +/- 154; after the second injection: 6 +/- 39 and after the third injection: 108 +/- 28, P less than 0.01 vs. the first dose). The effect of in vitro GHRH pretreatment on the subsequent response to GHRH was evaluated in monlayer cultures from 12 GH-secreting adenomas. At 10(-8) M, GHRH significantly stimulated GH release from 8 adenomas. The GHRH pretreatment that was effective in inducing desensitization in cultured rat anterior pituitary cells, i.e. preexposure of the cultured cells to 10(-8) M GHRH for 4 h at 37 C, did not abolish the GH response to the subsequent challenge with GHRH (mean percent stimulation: 150 +/- 14% in untreated cells vs. 153 +/- 30% in pretreated cells; P = NS). Only in one adenoma, did GHRH-promoted desensitization occur. No modification was found in GHRH unresponsive adenomas. In the adenomas, not only the efficacy but also the potency of GHRH on GH release after GHRH pretreatment was of the same order of magnitude as in untreated cells. No desensitization to GHRH action occurred when the pretreatment time was prolonged up to 8 h and the GHRH concentration in the preincubation medium was increased to 10(-7) M.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3102543     DOI: 10.1210/jcem-64-3-585

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  7 in total

Review 1.  Neuroendocrine regulation of human growth hormone secretion. Diagnostic and clinical applications.

Authors:  G Delitala; P Tomasi; R Virdis
Journal:  J Endocrinol Invest       Date:  1988-06       Impact factor: 4.256

Review 2.  Neuroendocrine tumors secreting growth hormone-releasing hormone: Pathophysiological and clinical aspects.

Authors:  Monica Gola; Mauro Doga; Stefania Bonadonna; Gherardo Mazziotti; Pier Paolo Vescovi; Andrea Giustina
Journal:  Pituitary       Date:  2006       Impact factor: 4.107

3.  Overexpression of the growth-hormone-releasing hormone gene in acromegaly-associated pituitary tumors. An event associated with neoplastic progression and aggressive behavior.

Authors:  K Thapar; K Kovacs; L Stefaneanu; B Scheithauer; D W Killinger; R V Lioyd; H S Smyth; A Barr; M O Thorner; B Gaylinn; E R Laws
Journal:  Am J Pathol       Date:  1997-09       Impact factor: 4.307

Review 4.  Genesis of pituitary adenomas: state of the art.

Authors:  G Faglia; A Spada
Journal:  J Neurooncol       Date:  2001-09       Impact factor: 4.130

5.  Effects of growth hormone-releasing hormone (GHRH) on densely granulated somatotroph adenomas and sparsely granulated somatotroph adenomas in vitro: a morphological and functional investigation.

Authors:  S Kawakita; S L Asa; K Kovacs
Journal:  J Endocrinol Invest       Date:  1989 Jul-Aug       Impact factor: 4.256

6.  Different GH responsiveness to repeated GHRH administration in normal children and adults.

Authors:  A Sartorio; A Spada; F Morabito; G Faglia
Journal:  J Endocrinol Invest       Date:  1988-11       Impact factor: 4.256

7.  Evaluation of IGF-I levels during long-term somatostatin analogs treatment in patients with gastroenteropancreatic endocrine tumors.

Authors:  C L Ronchi; M Peracchi; S Corbetta; S Massironi; C Ciafardini; D Conte; P Beck-Peccoz; A Spada
Journal:  J Endocrinol Invest       Date:  2007-03       Impact factor: 4.256

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.